Nifedipine Market Size, Share & Trends Analysis Report By Type (Nifedipine Controlled-Release Tablets, Nifedipine Extended Action Tablets), By Application (Primary Pulmonary Hypertension, Heart Failure, Raynaud’s Syndrome, Cephalalgia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region (North America, Asia-Pacific, Europe, Latin America, The Middle East and Africa) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

Nifedipine is a calcium channel blocker. It is frequently used to treat cardiovascular disorders, particularly hypertension (high blood pressure) and angina (chest discomfort). As a calcium channel blocker, Nifedipine inhibits the inflow of calcium ions into cardiac and smooth muscle cells, resulting in blood vessel relaxation and reduced heart workload.

An increase in the elderly population, healthcare spending, the prevalence of chronic illnesses such as heart failure, arrhythmias, and hypertension, and healthcare awareness are driving the nifedipine market share. However, government regulations and undesirable pharmacological effects such as hypotension, stomach ulcers, and congestive heart failure impede market growth. New development opportunities are likely to emerge from current R&D activities.

Market Dynamics

Global nifedipine market drivers

Aging population and chronic disease burden

Developed countries are witnessing a substantial demographic transition with an aging population. For example, countries in Europe, North America, and portions of Asia are seeing an increase in older adults. As people age, their chances of having chronic disorders like hypertension and cardiovascular disease rise. According to the World Health Organization (WHO), the proportion of individuals over 60 is predicted to nearly double by 2050, accounting for around 22% of the global population. This demographic shift is most noticeable in regions like Europe and North America. According to the American Heart Association (AHA), CVD affects around 40% of US men and women between the ages of 40 and 59, 75% between 60 and 79, and 86% over the age of 80.

As a result of the high prevalence of CVD, older persons place a significant load on the current US healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), roughly 65% of persons aged 60 and up have hypertension, underlining the condition's considerable burden among older populations. The aging population demographic trend, as well as the concomitant increase in chronic disease burden, such as hypertension, fuel demand for nifedipine-containing drugs. Nifedipine, a calcium channel blocker, is often used to treat hypertension and other cardiovascular disorders in older persons. As the population ages, there is a greater demand for effective chronic disease treatments, contributing to the nifedipine market trend.

Global nifedipine market restraints

Side-effects and tolerability issue

Nifedipine, like many other drugs, can cause adverse effects. Common side effects may include dizziness, flushing, headaches, and peripheral edema. Patients may encounter unacceptable side effects in some situations, limiting their ability to follow the specified treatment plan. For example, peripheral edema (lower extremity swelling) is a documented side effect of Nifedipine. While edema is often mild to moderate, some individuals may be uncomfortable or worrying. This adverse effect can have an impact on the patient's quality of life, prompting a choice to cease or alter the drug.

Furthermore, physicians may need to alter doses or closely monitor patients with adverse effects to provide the best combination of therapeutic advantages and tolerability. Physicians frequently engage in shared decision-making with patients, explaining potential side effects and weighing them against the benefits of Nifedipine for hypertension management. This collaborative approach tries to address patients' concerns and improve adherence.

Thus, side effects and tolerability difficulties can have a substantial impact on patient adherence to nifedipine therapy. Patients who experience annoying or intolerable side effects may be less likely to adhere to prescribed treatment regimens, resulting in inadequate management of hypertension and cardiovascular diseases.

Global nifedipine market opportunity

Innovation in drug delivery system

Extended-release versions of Nifedipine have been created to provide a sustained delivery of the medicine over time. This breakthrough intends to reduce drug concentration changes, lower dose frequency, and improve patient adherence. Adalat CC is a nifedipine-based extended-release medication. It is intended to gradually release the medicine, resulting in a constant therapeutic impact. This formulation manages hypertension using a once-daily dose schedule, which is convenient and may improve patient compliance. For example, one study published in the "American Journal of Therapeutics" evaluated the efficacy and safety of extended-release Nifedipine against immediate-release versions.

Furthermore, advances in drug delivery technologies market allow for novel formulations that improve Nifedipine's bioavailability and efficacy. Novel delivery techniques include nanoparticles, microparticles, and lipid-based formulations. Nanoparticle-based medication delivery methods for Nifedipine have been investigated. These nanoparticles can increase therapeutic solubility, stability, and targeted delivery. This method may improve the therapeutic efficacy of Nifedipine while reducing side effects.

Additionally, smart drug delivery systems are a popular topic in new drug delivery systems (NDDS). They can give precise targeting, regulated release, and the ability to overcome biological barriers. This can lead to improved therapeutic efficacy while reducing systemic adverse effects. Smart polymers that respond to pH changes or temperature differences could be used in nifedipine compositions. This would enable controlled drug release in response to specific physiological situations, improving therapeutic outcomes. As a result, these innovations seek to improve treatment outcomes, increase patient adherence, and address particular issues related to nifedipine therapy. Ongoing research and development in these areas help shape drug delivery systems for improving Nifedipine's efficacy in treating hypertension and cardiovascular disease.

Regional Analysis

The global nifedipine market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North america dominates the global market

North America is the most significant global nifedipine market shareholder and is estimated to grow at a CAGR of 8.5% over the forecast period.The increase is projected as chronic long-term illnesses become a more serious health hazard around the world. Furthermore, calcium channel-blocking medications such as Nicardipine, Norvasc, and Procardia, among others, have grown in the region following COVID-19, indicating an increase in acute and chronic health issues. Also, according to a TFAH report from 2023, 41.9% of adults in the United States are obese. Black and Latino individuals had the most excellent obesity rates, with 49.9% and 45.6%, respectively. Obesity rates are considerably greater in rural regions than in cities and suburbs. People's destructive lifestyles put them at risk for conditions such as high blood pressure, chest pain, and heart attacks. As a result, the general rate of drug use is increasing, which raises demand for Nifedipine.

Additionally, according to the Canadian Cardiovascular Society, IHD is the leading cause of lost years of life worldwide. The association also advises those who have active coronary artery disease, heart failure, and various types of valvular heart disease. As of February 2023, around 2.6 million Canadian people aged 20 and above have ischemic heart disease (IHD). IHD is the most frequent type of heart disease; hence, demand for Nifedipine in Canada is expected to increase during the projected period.

Furthermore, in 2021, the Mexican government stated that cardiovascular illnesses were responsible for approximately 226,000 fatalities. In 2018, cardiovascular illnesses were the top cause of mortality in Mexico, accounting for 141,619 deaths. Thirty percent of these deaths occurred in people under the age of 70. As of December 2020, Mexico's coronary heart disease (CHD) epidemic was continuously growing. Since 1980, the death rate from CHD has climbed by 48%. This is the primary reason for the increased demand for Nifedipine in the region.

Asia-Pacific is anticipated to exhibit a CAGR of 8.8% over the forecast period.The Asia-Pacific region is experiencing a substantial trend of increasing healthcare access in rural areas. Governments invest in healthcare infrastructure development, increasing the availability of Nifedipine. Telemedicine adoption is also growing, which improves patient access. Furthermore, there is an increase in collaboration between pharmaceutical corporations and local healthcare practitioners. For example, by the end of 2025, India's National Health Policy aims to reduce 25% of early cardiovascular deaths by screening and treating more than 80% of hypertensive people. Furthermore, the Rashtriya Arogya Nidhi (RAN) initiative assists patients below the poverty line, increasing market demand.

In addition, GlaxoSmithKline Plc (GSK), a significant player in the sector, has opted to invest USD 1 billion in its Indian pharmaceutical company, citing rising demand in emerging markets. At the same time, sales in established regions stagnate due to a wave of patent expirations. As part of the current India agreement, GSK aims to spend around USD 2 billion on two publicly traded Indian companies over the next year, representing the company's most significant incremental investment in any country. Furthermore, the obesity prevalence is high in Asia-Pacific. According to the Global Obesity Observatory, Nauru has the highest obesity incidence in the world, at 59.85%. According to Wisevoter, Nauru has a 61% obesity prevalence rate. Nauru is a small island nation in the South Pacific.

Europe has an increased emphasis on preventive healthcare. Government programs and public health campaigns raise cardiovascular health awareness, which increases demand for drugs such as Nifedipine. The market also sees a significant increase in research collaborations, which promotes breakthroughs in drug formulation and treatment methods. Furthermore, in the EU, 16.5% of individuals are obese, while 36.2% are pre-obesity. In 2019, the proportion of obese adults ranged from 10.9% in Romania and 28.7% in Malta. As the population grows, numerous ailments become more common, increasing the use of Nifedipine in the region.

Segmental Analysis

The global nifedipine market is segmented based on type, application, and distribution channel.

The market is further segmented by type into Nifedipine Controlled-Release Tablets and Nifedipine Extended Action Tablets.

Nifedipine-controlled-release tablets hold the highest revenue share of the market.

Nifedipine Controlled-Release Tablets

Nifedipine controlled-release tablets held the largest market share. Nifedipine controlled-release tablets are a pharmaceutical formulation that gradually releases the medication in the gastrointestinal tract. This controlled-release technique attempts to provide a more constant and long-lasting therapeutic effect while minimizing medication concentration changes. Controlled-release tablets are designed to distribute Nifedipine in a way that extends its duration of action, allowing for less frequent dosage than immediate-release forms. This improves patient convenience and adherence by lowering the number of daily dosages necessary.

The controlled-release formulation aids in managing disorders such as hypertension and angina by delivering Nifedipine in a consistent and controlled manner throughout time, enhancing its pharmacological effects. The rise in the prevalence of hypertension and heart failure, the use of cutting-edge technology for drug research, more funding from the government and international organizations, and rising knowledge of preventative treatment all contribute to the majority of the increase.

Nifedipine Extended Action Tablets

Nifedipine extended-action pills, also known as extended-release tablets, are intended to prolong the medication's release over time, resulting in a longer-lasting therapeutic impact. These tablets have a composition that allows for the progressive release of Nifedipine, resulting in a steady level of the medicine in the bloodstream. Extended-action pills are typically designed to be taken less frequently than immediate-release tablets, offering the advantage of once-daily dosing in some circumstances. This extended-release function aids in the management of illnesses such as hypertension and angina by ensuring that Nifedipine is delivered more consistently and steadily. The extended-action tablets are designed to promote patient adherence by providing a convenient dose schedule while effectively regulating blood pressure and cardiovascular symptoms for an extended period.

The market can be bifurcated by application into Primary Pulmonary Hypertension, Heart Failure, Raynaud's Syndrome, and Cephalalgia.

Primary Pulmonary Hypertension is the most common application in the market.

Primary Pulmonary Hypertension

Primary pulmonary hypertension had the highest ranking in 2023. Nifedipine is used to treat primary pulmonary hypertension, a rare and dangerous disorder defined by high blood pressure in the pulmonary arteries. As a vasodilator, Nifedipine helps reduce resistance in pulmonary blood arteries, relieving stress on the heart and boosting blood flow to the lungs. This application seeks to alleviate symptoms and improve the quality of life for those with primary pulmonary hypertension. Moreover, Obesity, bad dietary habits, excessive junk food consumption, a lack of exercise, a rising tendency among the younger generation to smoke and drink alcohol, and stress all contribute to the segment's domination. This area is expected to be driven by expanding government and private sector initiatives and industry projects aimed at developing sophisticated drugs to treat hypertension and diabetes.

Heart Failure

Nifedipine is used to treat heart failure, which occurs when the heart is unable to pump blood efficiently. As a calcium channel blocker, Nifedipine relaxes blood vessels and reduces the burden on the heart. This can help manage certain kinds of heart failure, particularly those related to hypertension. Nifedipine's vasodilatory properties help to increase cardiac output and circulation, treating several aspects of heart failure.

The market is sub-segmented into Hospital Pharmacies and retail Pharmacies based on distribution channels.

Hospital Pharmacies are the primary distribution channel.

Hospital Pharmacies

The hospital pharmacies category held a dominant share of the global market in 2023 and is expected to increase faster during the forecast period. 1Nifedipine is distributed by hospital pharmacies, which are essential parts of healthcare facilities. Hospital pharmacies play an important role in administering Nifedipine to both inpatients and outpatients under the supervision of healthcare experts. Hospital pharmacists help to ensure that Nifedipine is seamlessly integrated into the various treatment regimens given by healthcare experts in the hospital. This channel makes Nifedipine more accessible to patients undergoing inpatient treatment, outpatient visits, and specialized cardiovascular care.

Retail Pharmacies

Retail pharmacies are critical places of access for Nifedipine in the community. Patients can receive nifedipine prescriptions from their doctors and have them filled at retail pharmacies for self-administration at home. This distribution channel serves a larger audience, including those who manage chronic illnesses such as hypertension or angina as outpatients. Retail pharmacies provide the convenience of purchasing nifedipine drugs alongside other healthcare and wellness items.

Recent Developments

January 2024- GSK signed a deal to acquire Aiolos Bio.

January 2024- Novartis Lutathera®, a first-line treatment for individuals with advanced gastroenteropancreatic neuroendocrine tumors, lowered the probability of disease progression or death by 72%.

January 2024- Merck will acquire Harpoon Therapeutics, further diversifying its oncology pipeline.